Zai Lab (NASDAQ:ZLAB) Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.
The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies. In collaboration with global partners, Zai Lab has also brought Byooviz (ranibizumab-nuna), a biosimilar to Novartis’s Lucentis, to patients in China suffering from retinal vascular disorders. These flagship products are supported by a commercial infrastructure that spans sales, medical affairs and market access functions.
Zai Lab’s development pipeline extends across oncology, autoimmune and inflammatory diseases, neuroscience and infectious diseases. Key clinical programs include targeted therapies for solid tumors, antibody-drug conjugates licensed from international collaborators, and novel small molecules in preclinical stages. The company maintains licensing and development partnerships with leading global biopharma organizations to advance candidates in multiple geographies.
Since its founding in 2014, Zai Lab has grown into a fully integrated biopharmaceutical enterprise. Guided by an experienced leadership team with deep industry backgrounds, the company is committed to expanding its product offerings and geographic reach. Zai Lab continues to invest in innovation and global collaboration to address unmet medical needs and bring new therapies to patients worldwide.
